Janssen (Johnson & Johnson): Ad26.COV2.S

Vaccine Type: Non Replicating Viral Vector

Developers: Janssen Pharmaceutical Companies

This vaccine may also be referred to as Ad26COVS1, JNJ-78436735

Vaccine Trial & Approval Tracker

This vaccine has reached Phase 3 trials.

About Trial Phases

Phase 1: 2 Trials

Phase 2: 2 Trials

Phase 3: 2 Trials

  • NCT04505722
    Argentina, Brazil, Chile, Colombia, Mexico, Peru, Philippines, South Africa, Ukraine, United States of America
  • NCT04614948, ISRCTN14722499
    Belgium, Colombia, France, Germany, Philippines, South Africa, Spain, United Kingdom, United States of America

Approvals: 0 Approvals

This vaccine is not yet approved.

Registered Trials